Preliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors

被引：0
|
作者：
Johnson, M. [1 ]
Galsky, M. [2 ]
Barve, M. [3 ]
Goel, S. [4 ]
Park, H. [5 ]
Du, B. [6 ]
Mu, S. [7 ]
Ramakrishnan, V. [8 ]
Wood, K. [9 ]
Wang, V. [10 ]
Lakhani, N. [11 ]
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[2] Icahn Sch Med Mt Sinai, Hematol & Med Oncol, New York, NY 10029 USA
[3] Mary Crowley Canc Res, Med Oncol, Dallas, TX USA
[4] Montefiore Med Ctr, Med Oncol, 111 E 210th St, Bronx, NY 10467 USA
[5] Washington Univ, Med Oncol, St Louis, MO USA
[6] Beigene USA Inc, Pharmacovigilance & Drug Safety, San Mateo, CA USA
[7] BeiGene USA Inc, Clin Pharmacol, Ft Lee, NJ USA
[8] BeiGene USA Inc, CDx & Biomarker Dev, San Mateo, CA USA
[9] BeiGene USA Inc, Clin Sci, San Mateo, CA USA
[10] BeiGene USA Inc, Biostat, San Mateo, CA USA
[11] START Midwest, Dev Therapeut, Grand Rapids, MI USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
421P
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [21] Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors
    Plummer, Ruth
    Stephens, Peter
    Aissat-Daudigny, Louiza
    Cambois, Anne
    Moachon, Gilbert
    Brown, Peter D.
    Campone, Mario
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 257 - 265
  • [22] Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
    Xu, Jian-Ming
    Liu, Rongrui
    Ba, Yi
    Jiang, Da
    Wang, Mingxia
    Zheng, Yulong
    Wei, Jia
    Bai, Yu-Xian
    Lin, Lizhu
    Xiong, Jianping
    Zhu, Xixi
    Zhao, Chuanhua
    Jia, Ru
    Zhang, Yun
    Liu, Jianzhi
    Zhang, Gairong
    Li, Guangze
    Wang, Quanren
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
    Naito, Yoichi
    Kuboki, Yasutoshi
    Ikeda, Masafumi
    Harano, Kenichi
    Matsubara, Nobuaki
    Toyoizumi, Shigeyuki
    Mori, Yuko
    Hori, Natsuki
    Nagasawa, Takashi
    Kogawa, Takahiro
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1568 - 1576
  • [24] Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
    Yoichi Naito
    Yasutoshi Kuboki
    Masafumi Ikeda
    Kenichi Harano
    Nobuaki Matsubara
    Shigeyuki Toyoizumi
    Yuko Mori
    Natsuki Hori
    Takashi Nagasawa
    Takahiro Kogawa
    Investigational New Drugs, 2021, 39 : 1568 - 1576
  • [25] Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors
    Shapiro, Geoffrey I.
    Do, Khanh T.
    Tolaney, Sara M.
    Hilton, John F.
    Cleary, James M.
    Wolanski, Andrew
    Beardslee, Brian
    Hassinger, Faith
    Bhushan, Ketki
    Cai, Dongpo
    Downey, Elizabeth
    Pruitt-Thompson, Solida
    Barry, Suzanne M.
    Kochupurakkal, Bose
    Geradts, Joseph
    Unitt, Christine
    D'Andrea, Alan D.
    Muzikansky, Alona
    Piekarz, Richard
    Doyle, L. Austin
    Supko, Jeffrey
    CANCER RESEARCH, 2017, 77
  • [26] A PHASE 1 STUDY OF IPI-926, AN INHIBITOR OF THE HEDGEHOG PATHWAY, IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC SOLID TUMORS
    Rudin, C. M.
    Weiss, G. J.
    Chang, A.
    Gettinger, S.
    Miller, W. H.
    Eigl, B.
    Savage, A.
    Loewen, G.
    Ross, R. W.
    Jimeno, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 164 - 164
  • [27] A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.
    El-Khoueiry, Anthony B.
    Desai, Jayesh
    Iyer, Swaminathan Padmanabhan
    Gadgeel, Shirish M.
    Ramalingam, Suresh S.
    Horn, Leora
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
    Gerald S Falchook
    Jasgit Sachdev
    Esteban Rodrigo Imedio
    Sanjeev Kumar
    Ganesh M Mugundu
    Suzanne Jenkins
    Juliann Chmielecki
    Suzanne Jones
    David R Spigel
    Melissa Johnson
    Investigational New Drugs, 2023, 41 : 493 - 502
  • [29] A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
    Falchook, Gerald S.
    Sachdev, Jasgit
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Mugundu, Ganesh M.
    Jenkins, Suzanne
    Chmielecki, Juliann
    Jones, Suzanne
    Spigel, David R.
    Johnson, Melissa
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (03) : 493 - 502
  • [30] A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results
    Segal, Neil Howard
    Girda, Eugenia
    Sohal, Davendra
    Lakhani, Nehal J.
    Olszanski, Anthony J.
    Fong, Lawrence
    Kinnaman, Michael David
    Han, Hyunsil
    Skokos, Dimitris
    Casey, Kerry A.
    Wang, JuAn
    Wang, Bei
    Hao, Yi
    Li, Siyu
    Ganguly, Samit
    Lowy, Israel
    Seebach, Frank A.
    Mathias, Melissa Divya
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345